Kestra Medical insider plans sale of 8,759 shares

Kestra Medical Technologies, Ltd. has a notice of proposed sale of common stock by insider Timothy Moran under Rule 144.

Rhea-AI Filing Summary

Kestra Medical Technologies, Ltd. has a notice of proposed sale of common stock by insider Timothy Moran under Rule 144. The filing lists up to 8,759 shares of common stock to be sold through Merrill Lynch on NASDAQ, with an aggregate market value of $198,000.29 as of July 31, 2026. These shares relate to the vesting of performance share unit awards granted under the issuer’s equity compensation plan on July 17, 2026. The filing also reports that on July 30, 2026, Moran sold 4,117 shares of common stock for $93,758.64 within the past three months.

Key Figures

Shares proposed for sale: 8,759 shares Aggregate market value of proposed sale: $198,000.29 Recent shares sold: 4,117 shares +3 more

6 metrics

Shares proposed for sale 8,759 shares Common stock to be sold under Rule 144

Aggregate market value of proposed sale $198,000.29 Market value of 8,759 shares as of July 31, 2026

Recent shares sold 4,117 shares Common stock sold on July 30, 2026

Proceeds from recent sale $93,758.64 Value of 4,117 shares sold during the past three months

Vesting date of performance share units 07/17/2026 Vesting of performance share unit awards underlying the shares

Planned sale date reference 07/31/2026 Date associated with the proposed Rule 144 sale terms

Key Terms

Rule 144, performance share unit awards, equity compensation plan

3 terms

Rule 144 regulatory

"notice of proposed sale of common stock by insider Timothy Moran under Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

performance share unit awards financial

"vesting of performance share unit awards granted under the issuer’s equity compensation plan"

equity compensation plan financial

"granted as part of issuer equity compensation plan on July 17, 2026"

A plan by which a company gives employees, directors or contractors ownership or the right to buy ownership in the company through stock, options or similar awards — think of promising slices of the company pie as part of someone's pay. It matters to investors because these awards can change the number of shares outstanding, affect reported profits and influence management’s decisions; large or generous plans can dilute existing holders and alter incentives over time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Kestra Medical Technologies (KMTS) disclose in this Rule 144 filing?

The filing discloses that Timothy Moran intends to sell up to 8,759 shares of Kestra Medical common stock under Rule 144, with an aggregate market value of $198,000.29 as of July 31, 2026.

How many KMTS shares are covered by Timothy Moran’s planned Rule 144 sale?

The notice covers up to 8,759 shares of Kestra Medical Technologies common stock. These shares are associated with vested performance share unit awards granted under the company’s equity compensation plan on July 17, 2026.

What prior KMTS stock sale is reported in the past three months section?

The filing reports that on July 30, 2026, Timothy Moran sold 4,117 shares of Kestra Medical common stock for total proceeds of $93,758.64, as part of the required disclosure of securities sold during the past three months.

What is the reported market value of the KMTS shares proposed to be sold?

The proposed sale of 8,759 shares of Kestra Medical common stock has a reported aggregate market value of $198,000.29 as of July 31, 2026, based on the pricing information included in the Rule 144 filing.

How were the KMTS shares in the Rule 144 filing originally obtained?

The shares relate to the vesting of performance share unit awards on July 17, 2026. These awards were granted as part of the issuer’s equity compensation plan, according to the securities information disclosed in the filing.

Which broker and market are involved in the KMTS Rule 144 sale?

The proposed sale will be placed through Merrill Lynch, located at 225 Liberty Street, New York, NY. The shares are Kestra Medical common stock listed for trading on the NASDAQ market, as noted in the securities information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/31/2026 - 04:28 PM Accepted by SEC EDGAR 07/31/2026 - 04:27 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001753958
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	KESTRA MEDICAL TECHNOLOGIES, LTD.
SEC File Number	001-42549
Address of Issuer	3933 LAKE WASHINGTON BLVD NE SUITE 200 KIRKLAND WASHINGTON 98033
Phone	(425) 279-8002
Name of Person for Whose Account the Securities are To Be Sold	Moran Timothy P.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty Street Floor 37 New York NY 10281	8759	198000.29	58602497	07/31/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	07/17/2026	Vesting of performance share unit awards	KESTRA MEDICAL TECHNOLOGIES, LTD.			8759	07/17/2026	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Timothy Moran 3933 LAKE WASHINGTON BLVD NE SUITE 200 KIRKLAND WA 98033	Common Stock	07/30/2026	4117	93758.64

144: Remarks and Signature

Remarks
Date of Notice	07/31/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Timothy Moran
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)